Cancer stem cells as the relevant biomass for drug discovery

Area of Science:

• Oncology
• Cancer Biology
• Drug Discovery

Background:

• The limited success of current cancer chemotherapeutics may stem from inadequate targeting of aggressive, tumorigenic cells.
• Cancer stem cells (CSCs) are increasingly implicated as the primary drivers of tumor initiation and progression.
• CSCs exhibit inherent resistance to conventional chemotherapy and radiation therapy, posing a significant clinical challenge.

Purpose of the Study:

• To investigate the role of cancer stem cells (CSCs) in tumor aggressiveness and therapeutic resistance.
• To identify cellular pathways contributing to CSC insensitivity to standard cancer treatments.
• To explore strategies for the development of novel therapeutics targeting CSCs.

Main Methods:

• Analysis of primary tumor tissues (liquid and solid) to identify and characterize CSC populations.
• Investigation of cellular pathways responsible for CSC resistance mechanisms.
• Development of methods for CSC isolation and expansion for high-throughput screening.

Main Results:

• Emerging data confirm CSCs as the key cellular drivers of tumorigenicity across various cancer types.
• Specific cellular pathways have been identified as underlying the resistance of CSCs to conventional therapies.
• Progress has been made in isolating and expanding CSCs for drug screening.

Conclusions:

• Targeting cancer stem cells (CSCs) represents a promising strategy to improve the efficacy of cancer treatment.
• Understanding CSC resistance mechanisms is critical for designing effective anti-cancer therapies.
• Further research and optimized clinical trials are needed for the development of CSC-targeting agents.